IP Library Granted Patent US 7,105,328
Granted Patent B2
US 7,105,328 · App. 10/115,615 · Granted Sep 12, 2006

Methods for screening for compounds that modulate pd-1 signaling

Assignees: Dana-Farber Cancer Institute; Wyeth
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,105,328
App. No.
10/115,615
Granted
Sep 12, 2006
Kind
B2
Abstract

Disclosed are screening assays for identifying compounds which modulate the activity of, or signaling via, B7-4, or PD-1, especially which modulate the binding of B7-4 or PD-1 to a target molecule Further disclosed are a vaccine and also other compositions which contain agents that modulate signaling via PD-1.

Claims (14)

1. A method for screening for compounds which modulate PD-1 signaling comprising:

a) contacting a T cell activated in the presence of PD-L1 with a test compound;

b) contacting a T cell activated in the absence of PD-L1 with the test compound; and

c) determining the ability of the test compound to modulate phosphorylation of ERK 1 or ERK 2;

wherein modulation of phosphorylation of ERK 1 or ERK 2 in the presence of PD-L1 and not in the absence of PD-L1 indicates modulation of PD-1 signaling, thereby identifying a compound which modulates PD-1 signaling.

2. The method of claim 1 wherein the test compound upmodulates PD-1 signaling and thereby downmodulates of ERK 1 or ERK 2.

3. The method of claim 1 wherein the test compound downmodulates PD-1 signaling and thereby upmodulates of ERK 1 or ERK 2.

4. A method for screening for compounds which modulate PD-1 signaling comprising:

a) contacting a T cell activated in the presence of PD-L1 with a test compound;

b) contacting a T cell activated in the absence of PD-L1 with the test compound; and

c) determining the ability of the test compound to modulate phosphorylation of PKC-θ;

wherein modulation of phosphorylation of PKC-θ in the presence of PD-L1 and not in the absence of PD-L1 indicates modulation of PD-1 signaling, thereby identifying a compound which modulates PD-1 signaling.

5. The method of claim 4 wherein the test compound upmodulates PD-1 signaling and thereby downmodulates phosphorylation of PKC-θ.

6. The method of claim 4 wherein the test compound downmodulates PD-1 signaling and thereby upmodulates phosphorylation of PKC-θ.

Assignments (3)
CONFIRMATORY LICENSE Recorded Mar 17, 2015
From: DANA-FARBER CANCER INST
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 035212/0888 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 17, 2002
From: FREEMAN, GORDON J.
To: DANA-FARBER CANCER INSTITUTE
Reel/Frame 013301/0691 →
RE-RECORD TO CORRECT THE RECORDATION OF 09/12/2002 TO 09/17/2002, PREVIOUSLY RECORDED ON REEL 013301 FRAME 0685 (ASSIGNMENT OF ASSIGNOR'S INTEREST). Recorded Sep 17, 2002
From: WOOD, CLIVE; CHAUDHARY, DIVYA
To: WYETH
Reel/Frame 013416/0304 →
Continuity (2)
Provisional Application 6028106400 · Apr 2, 2001
Related Publication 20030044768A1 · Mar 6, 2003